8-K: Vivos Inc. Renews CEO's Employment Agreement with Increased Compensation

Vivos Inc. has renewed its employment agreement with CEO Michael Korenko, extending his term for two years with an increased base salary, stock grants, and potential bonuses.

Summary

• Vivos Inc. has entered into an amended and restated employment agreement with its Chief Executive Officer, Michael Korenko, effective January 1, 2024.
• The agreement extends Dr. Korenko's term as CEO for two years.
• His annual base salary will be $295,500, with a 4% annual increase.
• He will receive a grant of 20,000 restricted stock units, vesting in four equal installments over two years.
• Dr. Korenko is also eligible for a quarterly bonus of $10,000, contingent on conditions determined by the Board of Directors.
• The agreement includes standard provisions regarding confidentiality, non-competition, and non-solicitation.
• The new agreement replaces a previous version due to minor typographical errors.

Sentiment

Score: 7

Explanation: The document reflects a positive development for the company by securing its CEO for another two years. The terms of the agreement are standard and expected, indicating stability and continuity. The sentiment is moderately positive.

Positives

• The renewal of the CEO's contract provides stability and continuity in leadership.
• The increased base salary and potential bonuses may incentivize the CEO to perform well.
• The vesting schedule of the restricted stock units aligns the CEO's interests with the long-term success of the company.
• The inclusion of standard confidentiality, non-competition, and non-solicitation clauses protects the company's interests.

Negatives

• The bonus is discretionary and dependent on conditions set by the Board, which may create uncertainty.
• The vesting of the restricted stock units is spread over two years, which may not provide immediate motivation.

Risks

• The discretionary nature of the bonus could lead to dissatisfaction if the CEO's expectations are not met.
• The non-compete clause could be a point of contention if the CEO leaves the company in the future.
• The clawback provisions could create uncertainty for the CEO regarding compensation.

Future Outlook

The agreement provides a two-year term for the CEO, with potential for extension by mutual agreement, but neither party is obligated to agree to an extension.

Management Comments

• The Board of Directors has approved the renewed employment agreement with Dr. Michael Korenko.
• Dr. Korenko will continue to serve as Chief Executive Officer for a period of two years.

Industry Context

Executive employment agreements are common practice in publicly traded companies to secure leadership and align management interests with shareholder value. The terms of this agreement, including salary, bonuses, and stock options, are typical for a CEO of a company of this size and stage.

Comparison to Industry Standards

• The base salary of $295,500 is within the range for CEOs of small to mid-sized companies in the technology or biotech sectors, but may be lower than some larger, more established firms.
• The 20,000 restricted stock units are a common incentive, but the value will depend on the company's stock performance.
• The $10,000 quarterly bonus is relatively modest and is contingent on performance criteria set by the board, which is a standard practice.
• The two-year term is a typical length for executive employment agreements, providing a balance between stability and accountability.
• The inclusion of non-compete and confidentiality clauses is standard practice to protect the company's interests.

Stakeholder Impact

• Shareholders may view the renewal of the CEO's contract positively, as it provides stability and continuity in leadership.
• Employees may be reassured by the continued leadership of the CEO.
• The CEO is incentivized to perform well through the base salary, stock grants, and potential bonuses.

Next Steps

• The company will implement the terms of the employment agreement, including the payment of the base salary, the grant of restricted stock units, and the potential for quarterly bonuses.
• The Board of Directors will determine the conditions for the quarterly bonus payments.
• The company will continue to monitor the CEO's performance and compliance with the terms of the agreement.

Key Dates

Keywords

employment agreement, CEO, Michael Korenko, executive compensation, restricted stock units, bonus, non-compete, confidentiality, Vivos Inc.